Your browser doesn't support javascript.
loading
TNF compromises intestinal bile-acid tolerance dictating colitis progression and limited infliximab response.
Zheng, Mengqi; Zhai, Yunjiao; Yu, Yanbo; Shen, Jing; Chu, Shuzheng; Focaccia, Enrico; Tian, Wenyu; Wang, Sui; Liu, Xuesong; Yuan, Xi; Wang, Yue; Li, Lixiang; Feng, Bingcheng; Li, Zhen; Guo, Xiaohuan; Qiu, Ju; Zhang, Cuijuan; Hou, Jiajie; Sun, Yiyuan; Yang, Xiaoyun; Zuo, Xiuli; Heikenwalder, Mathias; Li, Yanqing; Yuan, Detian; Li, Shiyang.
Afiliação
  • Zheng M; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China.
  • Zhai Y; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Yu Y; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Shen J; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Chu S; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Focaccia E; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tian W; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Wang S; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Liu X; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Yuan X; Advanced Medical Research Institute, Shandong University, Jinan 250012, China.
  • Wang Y; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Li L; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Feng B; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Li Z; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Guo X; Institute for Immunology, School of Medicine, Tsinghua University, Beijing 100084, China; Beijing Key Laboratory for Immunological Research on Chronic Diseases, Tsinghua University, Beijing 100084, China.
  • Qiu J; CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
  • Zhang C; Institute of Pathology and Pathophysiology, Shandong University School of Medicine, Jinan 250012, China; Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Hou J; Cancer Centre, Faculty of Health Sciences University of Macau, Macau SAR, China; MOE Frontier Science Centre for Precision Oncology, University of Macau, Macau SAR, China.
  • Sun Y; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Yang X; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Zuo X; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Heikenwalder M; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; The M3 Research Center, Medical faculty, University Tübingen, Ottfried-Müller Strasse 37, Tübingen, Germany. Electronic address: m.heikenwaelder@dkfz.de.
  • Li Y; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Robot Engineering Lab
  • Yuan D; Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China. Electronic address: yuandt@sdu.edu.cn.
  • Li S; Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for Digestive Diseases, Jinan, China; Advanced Medical Research Institute, Shandong University, Jinan 250012, China; Key Laboratory for Experimental Teratology of M
Cell Metab ; 36(9): 2086-2103.e9, 2024 Sep 03.
Article em En | MEDLINE | ID: mdl-38971153
ABSTRACT
The intestine constantly encounters and adapts to the external environment shaped by diverse dietary nutrients. However, whether and how gut adaptability to dietary challenges is compromised in ulcerative colitis is incompletely understood. Here, we show that a transient high-fat diet exacerbates colitis owing to inflammation-compromised bile acid tolerance. Mechanistically, excessive tumor necrosis factor (TNF) produced at the onset of colitis interferes with bile-acid detoxification through the receptor-interacting serine/threonine-protein kinase 1/extracellular signal-regulated kinase pathway in intestinal epithelial cells, leading to bile acid overload in the endoplasmic reticulum and consequent apoptosis. In line with the synergy of bile acids and TNF in promoting gut epithelial damage, high intestinal bile acids correlate with poor infliximab response, and bile acid clearance improves infliximab efficacy in experimental colitis. This study identifies bile acids as an "opportunistic pathogenic factor" in the gut that would represent a promising target and stratification criterion for ulcerative colitis prevention/therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / Fator de Necrose Tumoral alfa / Infliximab Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / Fator de Necrose Tumoral alfa / Infliximab Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article